203P Telisotuzumab adizutecan (Temab-A, ABBV-400), a novel c-Met antibody-drug conjugate, in Asian patients (pts) with advanced CRC: Results of a phase I study

❌ 缺失

203P Telisotuzumab adizutecan (Temab-A, ABBV-400)，一种新型c-Met抗体-药物偶联物，在亚洲晚期结直肠癌患者中的疗效：一项I期研究结果

作者 Y. Kuboki; T. Nakajima; Y. Fujiwara; S. Kitano; B. O’Neil; D. Sommerhalder; M.R. Sharma; J. Powderly; J.H. Strickler; R. Perets; J. Cohen; J. Raimbourg; Z. Hunter; S. Quadri; M.E. Blaney; R.R. Li; A. Vasilopoulos; I. Abdelgawad; M. Burns; N. Yamamoto 期刊 Annals of Oncology 发表日期 2025 DOI 10.1016/j.annonc.2025.10.026 类型原创研究 (Original Research)